Shimoda Yusuke, Osanai Toshiya, Terasaka Syunsuke, Kobayashi Hiroyuki, Yamaguchi Shigeru, Endo Shogo, Hatanaka Kanako, Houkin Kiyohiro
Department of Neurosurgery, Hokkaido University Hospital.
No Shinkei Geka. 2016 Jul;44(7):555-60. doi: 10.11477/mf.1436203330.
Embosphere was approved in Japan for embolizing intracranial arteries for the reduction of intraoperative bleeding in January 2014. Until August 2015, we performed embolization for four meningiomas using Embosphere. We performed an initial evaluation of all the cases, including evaluation of the clinical courses, change in the maximum tumor diameters and volumes, alteration in the appearance on magnetic resonance imaging(MRI), amount of intraoperative bleeding, complications, and histopathological findings. After embolization, the maximum tumor diameters and volumes slightly decreased on MRI, whereas the signal change on diffusion-weighted imaging(DWI)or fluid-attenuated inversion recovery(FLAIR)varied in each case. One case demonstrated a partial signal change on DWI one day after the initial procedure, and another case demonstrated a decrease in perifocal edema on FLAIR. Among our patients, least bleeding was recorded at 6 days after the embolization. Histopathological analysis revealed coagulative necrotic lesions in two cases. The von Kossa stain was used to distinguish Embosphere from the psammoma body. One case involved a thromboembolic complication of the retinocentral artery caused by an Embosphere of 100-300 μm. Our early-stage experience suggests that an Embosphere of 300-500 μm should be used for safe embolization before resection to avoid thromboembolic complications because an Embosphere of 100-300 μm can pass through the dangerous anastomosis. Our present strategy was to resect the tumor approximately seven days after the embolization using Embosphere. However, further studies and discussion on the size of Embosphere, and the interval between pre-operative embolization and surgical removal are needed.
2014年1月,Embosphere在日本被批准用于栓塞颅内动脉以减少术中出血。截至2015年8月,我们使用Embosphere对4例脑膜瘤进行了栓塞治疗。我们对所有病例进行了初步评估,包括临床病程评估、最大肿瘤直径和体积的变化、磁共振成像(MRI)表现的改变、术中出血量、并发症以及组织病理学结果。栓塞后,MRI上最大肿瘤直径和体积略有减小,而弥散加权成像(DWI)或液体衰减反转恢复序列(FLAIR)上的信号变化在每个病例中各不相同。1例在初次手术后1天DWI上出现部分信号变化,另1例FLAIR上瘤周水肿减轻。在我们的患者中,栓塞后6天记录到的出血最少。组织病理学分析显示2例有凝固性坏死病变。采用冯·科萨染色将Embosphere与砂粒体区分开来。1例发生了由100 - 300μm的Embosphere引起视网膜中央动脉血栓栓塞并发症。我们的早期经验表明,由于100 - 300μm的Embosphere可通过危险吻合支,为避免血栓栓塞并发症,在切除术前进行安全栓塞应使用300 - 500μm的Embosphere。我们目前的策略是在使用Embosphere栓塞后约7天切除肿瘤。然而,关于Embosphere的大小以及术前栓塞与手术切除之间的间隔仍需要进一步研究和讨论。